Published in N Engl J Med on February 11, 2010
Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis | NCT00628719
Management of trypanosomiasis and leishmaniasis. Br Med Bull (2012) 1.78
Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control. PLoS Negl Trop Dis (2011) 1.64
Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. PLoS Negl Trop Dis (2010) 1.35
Liposomal amphotericin B as a treatment for human leishmaniasis. Expert Opin Emerg Drugs (2012) 1.24
Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes. J Antimicrob Chemother (2011) 1.19
Leishmaniasis: new insights from an old and neglected disease. Eur J Clin Microbiol Infect Dis (2011) 1.17
Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India. Am J Trop Med Hyg (2010) 1.17
Treatment of visceral leishmaniasis. J Glob Infect Dis (2010) 1.12
Paratransgenic control of vector borne diseases. Int J Biol Sci (2011) 1.06
An update on pharmacotherapy for leishmaniasis. Expert Opin Pharmacother (2014) 1.03
The development and clinical evaluation of second-generation leishmaniasis vaccines. Vaccine (2011) 1.03
Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh. Am J Trop Med Hyg (2011) 1.01
Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis. Chem Rev (2014) 1.00
Therapeutic options for visceral leishmaniasis. Drugs (2013) 1.00
Identification of new antileishmanial leads from hits obtained by high-throughput screening. Antimicrob Agents Chemother (2011) 1.00
Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects. Front Immunol (2014) 1.00
Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) in Bihar, India. PLoS Negl Trop Dis (2014) 1.00
Antiparasitic therapy. Mayo Clin Proc (2011) 0.98
Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India. PLoS Negl Trop Dis (2014) 0.97
Phase 4 pharmacovigilance trial of paromomycin injection for the treatment of visceral leishmaniasis in India. J Trop Med (2011) 0.96
Structures, targets and recent approaches in anti-leishmanial drug discovery and development. Open Med Chem J (2011) 0.95
Vaccines to prevent leishmaniasis. Clin Transl Immunology (2014) 0.94
Leishmaniasis in the United States: treatment in 2012. Am J Trop Med Hyg (2012) 0.94
Liposomal amphotericin B and leishmaniasis: dose and response. J Glob Infect Dis (2010) 0.92
The economic value of a visceral leishmaniasis vaccine in Bihar state, India. Am J Trop Med Hyg (2012) 0.92
Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: a phase 2 study. Am J Trop Med Hyg (2014) 0.91
Effectiveness and safety of short course liposomal amphotericin B (AmBisome) as first line treatment for visceral leishmaniasis in Bangladesh. PLoS Negl Trop Dis (2015) 0.89
Impact of ASHA training on active case detection of visceral leishmaniasis in Bihar, India. PLoS Negl Trop Dis (2014) 0.89
Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide. PLoS Negl Trop Dis (2014) 0.88
Evaluation of arylimidamides DB1955 and DB1960 as candidates against visceral leishmaniasis and Chagas' disease: in vivo efficacy, acute toxicity, pharmacokinetics, and toxicology studies. Antimicrob Agents Chemother (2012) 0.88
An oral formulation of amphotericin B attached to functionalized carbon nanotubes is an effective treatment for experimental visceral leishmaniasis. J Infect Dis (2011) 0.88
Elucidation of cellular mechanisms involved in experimental paromomycin resistance in Leishmania donovani. Antimicrob Agents Chemother (2014) 0.88
Drug resistance analysis by next generation sequencing in Leishmania. Int J Parasitol Drugs Drug Resist (2014) 0.87
Accelerated healing of cutaneous leishmaniasis in non-healing BALB/c mice using water soluble amphotericin B-polymethacrylic acid. Biomaterials (2011) 0.87
Five-year retrospective Italian multicenter study of visceral leishmaniasis treatment. Antimicrob Agents Chemother (2013) 0.86
A targeted and adjuvanted nanocarrier lowers the effective dose of liposomal amphotericin B and enhances adaptive immunity in murine cutaneous leishmaniasis. J Infect Dis (2013) 0.85
Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. Infect Dis Poverty (2016) 0.84
Molecular factors governing inhibition of arylimidamides against Leishmania: conservative computational modeling to improve chemotherapies. Bioorg Med Chem (2011) 0.84
Single-dose liposomal amphotericin B (AmBisome®) for the treatment of visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial. Trials (2011) 0.84
A Novel Molecular Test to Diagnose Canine Visceral Leishmaniasis at the Point of Care. Am J Trop Med Hyg (2015) 0.83
In vitro antileishmanial drug susceptibility of clinical isolates from patients with Indian visceral leishmaniasis--status of newly introduced drugs. Am J Trop Med Hyg (2012) 0.82
A species-specific approach to the use of non-antimony treatments for cutaneous leishmaniasis. Am J Trop Med Hyg (2011) 0.82
Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment. Eur J Clin Microbiol Infect Dis (2013) 0.81
Liposomal resiquimod for the treatment of Leishmania donovani infection. J Antimicrob Chemother (2013) 0.81
Feasibility of eliminating visceral leishmaniasis from the Indian subcontinent: explorations with a set of deterministic age-structured transmission models. Parasit Vectors (2016) 0.80
Strategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis. Vaccine (2016) 0.80
Targeting Ergosterol biosynthesis in Leishmania donovani: essentiality of sterol 14 alpha-demethylase. PLoS Negl Trop Dis (2015) 0.80
Introducing single dose liposomal amphotericin B for the treatment of visceral leishmaniasis in rural bangladesh: feasibility and acceptance to patients and health staff. J Trop Med (2014) 0.80
3D-QSAR based pharmacophore modeling and virtual screening for identification of novel pteridine reductase inhibitors. J Mol Model (2011) 0.79
Investigational drugs for visceral leishmaniasis. Expert Opin Investig Drugs (2014) 0.79
Challenges in the therapy of visceral leishmaniasis in Brazil: a public health perspective. J Trop Med (2013) 0.79
Recent developments and future prospects in the treatment of visceral leishmaniasis. Ther Adv Infect Dis (2016) 0.78
Co-infection of visceral leishmaniasis and HIV-1: a surviving case in China and review of treatment strategies. Emerg Microbes Infect (2014) 0.78
Elimination of visceral leishmaniasis on the Indian subcontinent. Lancet Infect Dis (2016) 0.78
Amphotericin B formulations and other drugs for visceral leishmaniasis. Am J Trop Med Hyg (2014) 0.78
The immunology of post-kala-azar dermal leishmaniasis (PKDL). Parasit Vectors (2016) 0.78
Therapeutic enhancement of protective immunity during experimental leishmaniasis. PLoS Negl Trop Dis (2011) 0.78
Drug targeting to infectious diseases by nanoparticles surface functionalized with special biomolecules. Curr Med Chem (2012) 0.78
SAR refinement of antileishmanial N(2),N(4)-disubstituted quinazoline-2,4-diamines. Bioorg Med Chem (2015) 0.78
Short-Course Treatment Regimen of Indian Visceral Leishmaniasis with an Indian Liposomal Amphotericin B Preparation (Fungisome™). Am J Trop Med Hyg (2015) 0.78
Sequential chemoimmunotherapy of experimental visceral leishmaniasis using a single low dose of liposomal amphotericin B and a novel DNA vaccine candidate. Antimicrob Agents Chemother (2015) 0.78
Oral azithromycin versus its combination with miltefosine for the treatment of experimental Old World cutaneous leishmaniasis. J Parasit Dis (2014) 0.77
Association of liposome-encapsulated trivalent antimonial with ascorbic acid: an effective and safe strategy in the treatment of experimental visceral leishmaniasis. PLoS One (2014) 0.77
Comparison of point-of-care tests for the rapid diagnosis of visceral leishmaniasis in East African patients. Am J Trop Med Hyg (2014) 0.77
Visceral leishmaniasis. Trop Parasitol (2015) 0.77
Antileishmanial activity, uptake, and biodistribution of an amphotericin B and poly(α-Glutamic Acid) complex. Antimicrob Agents Chemother (2013) 0.77
Combined Immune Therapy for the Treatment of Visceral Leishmaniasis. PLoS Negl Trop Dis (2016) 0.76
The Leishmaniasis East Africa Platform (LEAP): strengthening clinical trial capacity in resource-limited countries to deliver new treatments for visceral leishmaniasis. Trans R Soc Trop Med Hyg (2016) 0.76
Case report: Acute renal injury as a result of liposomal amphotericin B treatment in sodium stibogluconate unresponsive visceral leishmaniasis. Am J Trop Med Hyg (2011) 0.75
Hypokalaemia-induced rhabdomyolysis after treatment of post-Kala-azar dermal Leishmaniasis (PKDL) with high-dose AmBisome in Bangladesh-a case report. PLoS Negl Trop Dis (2014) 0.75
Clinical Challenges in the Management of Leishmania/HIV Coinfection in a Nonendemic Area: A Case Report. Case Rep Infect Dis (2012) 0.75
Plasticity of the Leishmania genome leading to gene copy number variations and drug resistance. F1000Res (2016) 0.75
Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia. BMC Infect Dis (2016) 0.75
Identification and characterization of the regions involved in the nuclear translocation of the heterodimeric leishmanial DNA topoisomerase IB. PLoS One (2013) 0.75
Liposomal systems as carriers for bioactive compounds. Biophys Rev (2015) 0.75
Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh. PLoS Negl Trop Dis (2017) 0.75
Telehealth: a perspective approach for visceral leishmaniasis (kala-azar) control in India. Pathog Glob Health (2012) 0.75
Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions. Drugs (2016) 0.75
New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas. Drug Dev Res (2011) 0.75
Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme. Clin Drug Investig (2017) 0.75
Visceral Leishmaniasis as a Possible Reason for Pancytopenia. Front Pediatr (2015) 0.75
Nanostructured delivery systems with improved leishmanicidal activity: a critical review. Int J Nanomedicine (2017) 0.75
Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum. PLoS Negl Trop Dis (2017) 0.75
Prevalence, severity, and pathogeneses of anemia in visceral leishmaniasis. Parasitol Res (2016) 0.75
Diagnostic accuracy of pulmonary embolism rule-out criteria: a systematic review and meta-analysis. Ann Emerg Med (2011) 3.49
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet (2011) 2.81
Longlasting insecticidal nets for prevention of Leishmania donovani infection in India and Nepal: paired cluster randomised trial. BMJ (2010) 2.30
High incidence of zidovudine induced anaemia in HIV infected patients in eastern India. Indian J Med Res (2010) 2.11
Leishmaniasis: an update of current pharmacotherapy. Expert Opin Pharmacother (2012) 2.03
Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis (2012) 2.00
Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis (2004) 1.85
Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a systematic review. Respirology (2010) 1.84
A subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan. J Exp Med (2004) 1.81
Development of a clinical prediction rule for 30-day cardiac events in emergency department patients with chest pain and possible acute coronary syndrome. Ann Emerg Med (2011) 1.78
Rapid, noninvasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic strip tests for detection of anti-K39 antibody. J Clin Microbiol (2006) 1.75
Availability of miltefosine for the treatment of kala-azar in India. Bull World Health Organ (2005) 1.53
New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis (2008) 1.51
Performance of a rectilinear biphasic waveform in defibrillation of presenting and recurrent ventricular fibrillation: a prospective multicenter study. Resuscitation (2011) 1.42
Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. Clin Infect Dis (2007) 1.39
Primary neuroendocrine mediastinal tumor presenting with carcinoid syndrome and left supraclavicular lymphadenopathy: clinico-radiological and pathological features. J Cancer Res Ther (2013) 1.38
Longitudinal seroepidemiologic study of visceral leishmaniasis in hyperendemic regions of Bihar, India. Am J Trop Med Hyg (2009) 1.34
IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. J Infect Dis (2011) 1.33
Kala-azar--progress against a neglected disease. N Engl J Med (2002) 1.33
The epidemiology of Leishmania donovani infection in high transmission foci in India. Trop Med Int Health (2010) 1.30
Advances in the treatment of leishmaniasis. Curr Opin Infect Dis (2002) 1.27
Antileishmanial activity of nano-amphotericin B deoxycholate. J Antimicrob Chemother (2008) 1.26
Evaluation of leishmanin skin test in Indian visceral leishmaniasis. Am J Trop Med Hyg (2009) 1.22
Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes. J Antimicrob Chemother (2011) 1.19
Diagnostic accuracy of endobronchial ultrasound-guided transbronchial needle biopsy in mediastinal lymphadenopathy: a systematic review and meta-analysis. Respir Care (2011) 1.18
Antimony toxicity. Int J Environ Res Public Health (2010) 1.15
Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. Nat Genet (2013) 1.15
Diagnostic accuracy of the TIMI risk score in patients with chest pain in the emergency department: a meta-analysis. CMAJ (2010) 1.14
Diagnosis of Indian visceral leishmaniasis by nucleic acid detection using PCR. PLoS One (2011) 1.14
Population preference of net texture prior to bed net trial in Kala-Azar-endemic areas. PLoS Negl Trop Dis (2007) 1.13
Treatment of visceral leishmaniasis. Expert Opin Pharmacother (2005) 1.11
Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial. Trop Med Int Health (2012) 1.09
Serological markers of sand fly exposure to evaluate insecticidal nets against visceral leishmaniasis in India and Nepal: a cluster-randomized trial. PLoS Negl Trop Dis (2011) 1.08
CD8 T cell exhaustion in human visceral leishmaniasis. J Infect Dis (2013) 1.06
Microbiological and clinical characteristics of diabetic foot infections in northern India. J Infect Dev Ctries (2012) 1.03
Paromomycin in the treatment of leishmaniasis. Expert Opin Investig Drugs (2008) 1.03
External validation of the Glasgow-Blatchford Bleeding Score and the Rockall Score in the US setting. Am J Emerg Med (2012) 1.03
An update on pharmacotherapy for leishmaniasis. Expert Opin Pharmacother (2014) 1.03
Primary tuberculous glossitis in an immunocompetent patient. Hong Kong Med J (2007) 1.02
Drugs against leishmaniasis: a synergy of technology and partnerships. Trends Parasitol (2004) 1.00
Risk of Clostridium difficile infection with acid-suppressive therapy; pitfalls in accurate estimation. Am J Gastroenterol (2013) 1.00
Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment. Clin Infect Dis (2009) 0.99
Tuberculosis of spleen presenting with pyrexia of unknown origin in a non-immunocompromised woman. Lung India (2008) 0.93
Evaluation of brain stem auditory evoked potentials in stable patients with chronic obstructive pulmonary disease. Ann Thorac Med (2008) 0.93
Liposomal amphotericin B and leishmaniasis: dose and response. J Glob Infect Dis (2010) 0.92
Recent advances in the diagnosis and treatment of kala-azar. Natl Med J India (2012) 0.92
The use of an electronic medical record based automatic calculation tool to quantify risk of unplanned readmission to the intensive care unit: a validation study. J Crit Care (2011) 0.92
In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis. Am J Trop Med Hyg (2013) 0.92
Distinct autoantibody profiles in systemic lupus erythematosus patients are selectively associated with TLR7 and TLR9 upregulation. J Clin Immunol (2013) 0.91
Unusual case of resistance to amphotericin B in visceral leishmaniasis in a region in India where leishmaniasis is not endemic. J Clin Microbiol (2011) 0.91
Correlation between high-resolution computed tomography features and patients' characteristics in chronic obstructive pulmonary disease. Ann Thorac Med (2008) 0.90
Cardioembolic but not other stroke subtypes predict mortality independent of stroke severity at presentation. Stroke Res Treat (2011) 0.90
Seasonal variation in the prevalence of sand flies infected with Leishmania donovani. PLoS One (2013) 0.89
Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India. Future Microbiol (2010) 0.89
Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis. Clin Infect Dis (2006) 0.88
An oral formulation of amphotericin B attached to functionalized carbon nanotubes is an effective treatment for experimental visceral leishmaniasis. J Infect Dis (2011) 0.88
Profound interferon gamma deficiency in patients with chronic pulmonary nontuberculous mycobacteriosis. Am J Med (2002) 0.88
Noninvasive molecular diagnosis of human visceral leishmaniasis. J Clin Microbiol (2011) 0.88
Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine. Trans R Soc Trop Med Hyg (2005) 0.88
Genetic and functional evaluation of the role of DLL1 in susceptibility to visceral leishmaniasis in India. Infect Genet Evol (2012) 0.88
Genetic and functional evaluation of the role of CXCR1 and CXCR2 in susceptibility to visceral leishmaniasis in north-east India. BMC Med Genet (2011) 0.87
Clinical and imaging perspective and unanswered questions in a case of metronidazole induced encephalopathy. Ann Indian Acad Neurol (2013) 0.86
No evidence for association between SLC11A1 and visceral leishmaniasis in India. BMC Med Genet (2011) 0.86
Significance of noseclips during spirometric maneuver in patients with COPD. J Assoc Physicians India (2006) 0.85
Retracted Validity of existing CD4+ classification in north Indians, in predicting immune status. J Infect (2005) 0.85
Classification and regression tree and spatial analyses reveal geographic heterogeneity in genome wide linkage study of Indian visceral leishmaniasis. PLoS One (2010) 0.84
Ambisome plus miltefosine for Indian patients with kala-azar. Trans R Soc Trop Med Hyg (2010) 0.84
ST-segment elevation in non-atherosclerotic coronaries: a brief overview. Intern Emerg Med (2010) 0.84
A novel defect in interferon-gamma secretion in patients with refractory nontuberculous pulmonary mycobacteriosis. Ann Intern Med (2003) 0.84
Identification and characterization of a novel Leishmania donovani antigen for serodiagnosis of visceral leishmaniasis. Am J Trop Med Hyg (2012) 0.83
Assessment of visual evoked potentials in stable COPD patients with no visual impairment. Ann Thorac Med (2010) 0.83
Prevalence of sand flies and Leishmania donovani infection in a natural population of female Phlebotomus argentipes in Bihar State, India. Vector Borne Zoonotic Dis (2012) 0.82
Evaluation of rk39 immunochromatographic test with urine for diagnosis of visceral leishmaniasis. Trans R Soc Trop Med Hyg (2011) 0.82
In vitro antileishmanial drug susceptibility of clinical isolates from patients with Indian visceral leishmaniasis--status of newly introduced drugs. Am J Trop Med Hyg (2012) 0.82
Central Nervous System Cryptococcosis among a Cohort of HIV Infected Patients from a University Hospital of North India. J Clin Diagn Res (2012) 0.82
Cutaneous Leishmaniasis: Current Treatment Practices in the USA for Returning Travelers. Curr Treat Options Infect Dis (2015) 0.81
Drug resistant tuberculous osteomyelitis of small bones of foot. J Assoc Physicians India (2005) 0.81
Differential microRNA profile and post-transcriptional regulation exist in systemic lupus erythematosus patients with distinct autoantibody specificities. J Clin Immunol (2014) 0.81
Non-oral treatment with ivermectin for disseminated strongyloidiasis. Am J Trop Med Hyg (2010) 0.81
Evaluation of two novel rapid rKE16 antigen-based tests for diagnosis of visceral leishmaniasis in India. J Clin Microbiol (2012) 0.81
A Correlative Study of Splenic Parasite Score and Peripheral Blood Parasite Load Estimation by Quantitative PCR in Visceral Leishmaniasis. J Clin Microbiol (2015) 0.81
Utility of semirigid thoracoscopy in the diagnosis of pleural effusions: a systematic review. J Bronchology Interv Pulmonol (2010) 0.80
Ultrasonography for diagnosis of abdominal tuberculosis in HIV infected people. Indian J Med Res (2010) 0.80
rK39 antigen for the diagnosis of visceral leishmaniasis by using human saliva. Am J Trop Med Hyg (2012) 0.79
Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status. Pediatr Infect Dis J (2016) 0.79
Investigational drugs for visceral leishmaniasis. Expert Opin Investig Drugs (2014) 0.79
Hepatocellular carcinoma presenting as neutrophilic leukaemoid reaction--a rare entity. J Indian Med Assoc (2007) 0.79